<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1579">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140603</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-DOR-2021-01</org_study_id>
    <nct_id>NCT05140603</nct_id>
  </id_info>
  <brief_title>Ambispective Cohort Study to Evaluate the Efficacy, Safety, and Tolerance of an Antiretroviral Regimen With Doravirine</brief_title>
  <official_title>Ambispective Cohort Study to Evaluate the Effectiveness, Safety and Tolerance of a Doravirine-based Antirretroviral Regimen as a Switching Strategy in Virologically Supressed HIV Infected Patients: Real-world Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, ambispective single-center cohort study, including 150 patients who received&#xD;
      or are receiving a doravirine-based regimen plus two NRTI or a dual therapy of doravirine&#xD;
      plus dolutegravir (DTG) or bDRV in routinely clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational, ambispective single-center cohort study, including 150 patients who received&#xD;
      or are receiving a doravirine-based regimen plus two NRTI or a dual therapy of doravirine&#xD;
      plus dolutegravir (DTG) or bDRV in routinely clinical practice.&#xD;
&#xD;
      All patients who were switched to a doravirine-based regimen from date of its availability in&#xD;
      the center (September 2020) due to clinical considerations and have available records will be&#xD;
      retrospectively included until date of study approval (expected on July 2021).&#xD;
&#xD;
      Minor resistances in a basal genotype to NNRTI or previous failure to NNRTI as nevirapine or&#xD;
      efavirenz will be accepted if doravirine it is combined with a high genetic barrier drug with&#xD;
      complete activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with an HIV-1 viral load ≤ 50 and ≤ 200* copies/ml using snapshot algorithm.</measure>
    <time_frame>Up to 96 weeks.</time_frame>
    <description>FDA snapshot algorithm (ITT-exposed).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of changes in renal biomarkers.</measure>
    <time_frame>Up to 48 weeks.</time_frame>
    <description>Changes in renal biomarkers from baseline (mean absolute changes in glomerular filtrate estimation (eGFR and CKD-epi equation)/24 (interim analysis) and 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of changes in hepatic parameters.</measure>
    <time_frame>Up to 48 weeks.</time_frame>
    <description>Changes in hepatic parameters from baseline (median percentage of change in ASL, AST, GGT, AF and bilirubin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of changes in lipid parameters.</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Changes in lipid parameters from baseline (median percentage of change in total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, CT-HDL ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability rate of study patients.</measure>
    <time_frame>Up to 48 weeks.</time_frame>
    <description>Number of interactions, adverse events and toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death rates among trial patients.</measure>
    <time_frame>Up to 48 weeks.</time_frame>
    <description>Number of patients who died during or after the trial.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients who received a doravirine-based regimen.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who were switched to a doravirine-based regimen from the date of its&#xD;
        availability in our center (September 2020) due to clinical considerations and have records&#xD;
        available will be retrospectively included until the study approval date (expected July&#xD;
        2021).&#xD;
&#xD;
        Minor resistances in a baseline genotype to NNRTI or prior failure to NNRTI such as&#xD;
        nevirapine or efavirenz will be accepted if doravirine is combined with a fully active high&#xD;
        genetic barrier drug.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older than 18 years HIV-1 infected subjects.&#xD;
&#xD;
          -  Switched to a doravirine-based ART regimen under clinician criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Doravirine major resistance mutations (accessory mutations are allowed).&#xD;
&#xD;
          -  Major mutations to any of the other drugs combined with doravirine.&#xD;
&#xD;
          -  Pregnancy, active tuberculosis or any condition that contraindicate the use of&#xD;
             doravirine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuria Espinosa Aguilera</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virgen del Rocío University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuria Espinosa Aguilera</last_name>
    <phone>955 01 30 98</phone>
    <email>nuriai.espinosa.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos García Pérez</last_name>
    <phone>955 04 31 27</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Nuria Espinosa Aguilera</last_name>
      <phone>955 01 30 98</phone>
      <email>nuriai.espinosa.sspa@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Carlos García Pérez</last_name>
      <phone>955 04 31 27</phone>
      <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

